HC Wainwright Estimates Immunocore FY2029 Earnings

Immunocore Holdings plc (NASDAQ:IMCR) – Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Immunocore in a note issued to investors on Monday, January 27th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of $7.53 per share for the year. HC Wainwright currently has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share.

A number of other research firms have also issued reports on IMCR. UBS Group began coverage on Immunocore in a report on Thursday, October 24th. They issued a “sell” rating and a $24.00 target price on the stock. Guggenheim cut Immunocore from a “buy” rating to a “neutral” rating in a research report on Monday, October 7th. Mizuho downgraded Immunocore from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. Needham & Company LLC restated a “buy” rating and set a $71.00 target price on shares of Immunocore in a report on Friday, January 10th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $35.00 price target (down previously from $74.00) on shares of Immunocore in a report on Friday, December 13th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $65.64.

Immunocore Trading Down 2.2 %

IMCR opened at $32.26 on Tuesday. The business’s 50 day moving average is $30.55 and its two-hundred day moving average is $33.28. Immunocore has a 52 week low of $27.69 and a 52 week high of $76.98. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The firm has a market cap of $1.61 billion, a price-to-earnings ratio of -33.96 and a beta of 0.76.

Immunocore (NASDAQ:IMCR) last posted its earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.33) by $0.50. The firm had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. Immunocore’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.59) earnings per share.

Institutional Investors Weigh In On Immunocore

Hedge funds and other institutional investors have recently made changes to their positions in the business. Primecap Management Co. CA boosted its stake in Immunocore by 26.7% in the 3rd quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock worth $76,954,000 after buying an additional 520,950 shares during the last quarter. State Street Corp boosted its position in shares of Immunocore by 63.9% in the third quarter. State Street Corp now owns 76,671 shares of the company’s stock worth $2,387,000 after acquiring an additional 29,897 shares during the last quarter. Principal Financial Group Inc. grew its holdings in Immunocore by 25.0% in the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock valued at $17,007,000 after purchasing an additional 109,206 shares during the period. Hennion & Walsh Asset Management Inc. increased its position in Immunocore by 125.4% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company’s stock worth $1,463,000 after purchasing an additional 27,598 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Immunocore by 7,437.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,257 shares of the company’s stock worth $2,872,000 after purchasing an additional 91,033 shares during the period. Hedge funds and other institutional investors own 84.50% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.